Results: The first-line bDMARD of choice was IL-6 inhibitor (83.1%), 29.1% of patients switching to the second biologic drug (the most common being TNF inhibitor), The maintenance time of the IL-6 inhibitor group was 131 weeks (CI95%: 108, 2 - 153, 8), of the TNF inhibitor group was 46 weeks (CI95%: 10, 4 - 81, 6) (p=0.007).